Pear Therapeutics, Inc. (PEAR)

Pear Therapeutics, Inc. (PEAR) Healthcare & Pipeline Overview

Pear Therapeutics, Inc. is a commercial-stage digital therapeutics company pioneering software-based treatments for central nervous system disorders and other conditions. With FDA-approved products like reSET, reSET-O, and Somryst, alongside a robust 14-product pipeline, it aims to address unmet medical needs through novel digital health solutions.

What Is the Investment Thesis for PEAR?

Pear Therapeutics, Inc. presents a unique investment profile centered on its pioneering role in prescription digital therapeutics (PDTs). The company's commercial-stage products, reSET, reSET-O, and Somryst, address significant unmet medical needs in substance use disorders, opioid use disorder, and chronic insomnia, respectively. These FDA-approved software-based treatments represent a novel approach to healthcare delivery, leveraging digital technology for therapeutic intervention. A key value driver is the extensive development pipeline of 14 investigational products spanning psychiatry, neurology, and non-central nervous system conditions, which offers substantial future growth potential through new market entries and therapeutic expansions. However, the company faces significant financial challenges, as evidenced by its -187.0% profit margin and current market capitalization. Achieving profitability and securing sustained funding are critical for realizing the potential of its innovative platform and pipeline. The long-term success hinges on broader adoption of PDTs by healthcare systems, favorable reimbursement policies, and the successful commercialization of its pipeline assets.

Based on FMP financials and quantitative analysis

PEAR Key Highlights

• Market Capitalization: $0.00B, indicating a very small market valuation.
• Profit Margin: -187.0%, reflecting substantial ongoing losses relative to revenue.
• Gross Margin: 35.5%, suggesting a positive margin on product sales before operating expenses.
• Beta: 0.52, indicating lower volatility compared to the broader market.
• Employee Count: 200 employees, supporting its commercial and development operations.

Who Are PEAR's Competitors?

PEAR is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are PEAR's Key Strengths?

• Pioneering position in the prescription digital therapeutics (PDT) market with FDA-approved products.
• Diverse and extensive development pipeline of 14 investigational products.
• Addresses significant unmet medical needs in substance use disorders, opioid use disorder, and chronic insomnia.
• Leverages technology for scalable and accessible therapeutic interventions.

What Are PEAR's Weaknesses?

• Significant ongoing financial losses, indicated by a -187.0% profit margin.
• Current market capitalization of $4.09M highlights substantial financial challenges.
• Requires substantial further funding to sustain operations and commercialize pipeline assets.
• Reliance on evolving regulatory and reimbursement frameworks for digital therapeutics.

What Could Drive PEAR Stock Higher?

• Regulatory approvals for new prescription digital therapeutics from its 14-product pipeline, potentially opening new market segments in psychiatry, neurology, or non-central nervous system conditions.
• Expansion of commercialization efforts for reSET, reSET-O, and Somryst, including securing broader payer coverage and increasing prescriber adoption rates across healthcare systems.
• Successful completion of strategic partnerships or collaborations that could provide additional funding, accelerate market access, or enhance product development capabilities.
• Continued progress in clinical trials for investigational products, demonstrating efficacy and safety data necessary for future regulatory submissions and market entry.

What Are the Key Risks for PEAR?

• Financial-distress signal — its Altman Z-Score of -6.61 sits in the distress zone (elevated bankruptcy risk).
• Negative return on equity (-39.2%) — the business is not currently generating profit on shareholder capital.
• Significant financial challenges, including a -187.0% profit margin and a very low market capitalization, indicating a critical need for improved financial performance and sustained funding.
• Uncertainty surrounding future funding rounds and capital raises, which are essential for supporting ongoing operations, research and development, and commercialization efforts.
• Regulatory hurdles and potential delays in obtaining approvals for its extensive pipeline of 14 investigational digital therapeutics, which could impact future revenue streams.
• Market adoption and reimbursement challenges for prescription digital therapeutics, as the healthcare system continues to adapt to this novel treatment modality.
• Intense competition from other digital health companies, traditional pharmaceutical firms, and technology companies entering the healthcare space, potentially impacting market share and pricing.

What Are the Growth Opportunities for PEAR?

• Expansion of Commercialized PDTs: Pear Therapeutics has an opportunity to expand the market penetration and adoption of its existing FDA-approved products: reSET, reSET-O, and Somryst. This involves broadening prescriber networks, securing favorable reimbursement coverage from more payers, and potentially exploring international markets. The addressable market for substance use disorders, opioid use disorder, and chronic insomnia is substantial, and increased awareness among healthcare providers and patients about the efficacy and accessibility of digital therapeutics could significantly drive revenue growth. Strategic marketing and educational initiatives are crucial for unlocking this growth, with a potential timeline of ongoing expansion over the next 3-5 years.
• Advancement and Commercialization of Pipeline Products: The company's robust pipeline of 14 investigational products represents a significant long-term growth driver. These treatments span diverse and high-need therapeutic areas such as psychiatry, neurology, gastrointestinal, oncological, and cardiovascular disorders. Successfully navigating clinical trials, securing regulatory approvals, and subsequently launching these new PDTs would unlock entirely new revenue streams and market segments. Each successful launch could significantly expand Pear's total addressable market and diversify its product portfolio, reducing reliance on current offerings. The timeline for this opportunity is staggered, with potential new product launches occurring over the next 5-10 years.
• Strategic Partnerships and Collaborations: Pear Therapeutics can leverage its expertise in developing and commercializing FDA-approved PDTs through strategic partnerships with pharmaceutical companies, healthcare systems, and technology firms. These collaborations could facilitate broader distribution, co-development of new digital therapeutics, or integration of Pear's platforms into existing healthcare infrastructure. Such partnerships could provide access to larger patient populations, enhance market reach, and potentially provide non-dilutive funding for research and development. This strategy could accelerate market adoption and reduce commercialization risks, with potential partnerships forming over the next 2-4 years.
• Favorable Regulatory and Reimbursement Environment: The evolving regulatory landscape for digital therapeutics, particularly in the US, presents a growth opportunity. As regulatory bodies like the FDA continue to refine pathways for PDTs, and as payers increasingly recognize their clinical and economic value, the market for Pear's products could expand significantly. Clearer reimbursement codes and policies would streamline patient access and incentivize prescribers. Advocacy efforts and continued generation of real-world evidence demonstrating cost-effectiveness and improved patient outcomes are critical to shaping this environment, with ongoing developments expected over the next 1-3 years.
• Technological Innovation and Platform Enhancement: Continuous investment in research and development to enhance the underlying technology platform and user experience of its digital therapeutics can drive growth. This includes incorporating advanced AI/ML capabilities, improving patient engagement features, and ensuring seamless integration with electronic health records (EHRs) and other healthcare IT systems. A superior, more integrated platform can differentiate Pear's offerings, improve patient adherence and outcomes, and attract more healthcare providers. This ongoing innovation ensures the company remains at the forefront of digital therapeutics, maintaining a competitive edge over the long term.

What Opportunities Does PEAR Have?

• Expansion into new therapeutic areas through its robust development pipeline.
• Increased adoption of digital health solutions and telemedicine by healthcare providers and patients.
• Potential for strategic partnerships with pharmaceutical companies or healthcare systems.
• Favorable shifts in regulatory and reimbursement policies for prescription digital therapeutics.

What Threats Does PEAR Face?

• Intense competition from other digital health companies, traditional pharma, and tech giants.
• Regulatory hurdles and delays in securing approvals for new pipeline products.
• Challenges in securing adequate reimbursement coverage from payers, limiting market access.
• Need for significant capital raises, potentially leading to shareholder dilution.

What Are PEAR's Competitive Advantages?

• FDA-Approved Products: Pear Therapeutics has secured FDA authorization for its key products (reSET, reSET-O, Somryst), establishing a regulatory barrier to entry for competitors.
• Extensive Pipeline: A robust pipeline of 14 investigational products across diverse therapeutic areas provides future growth potential and a broad intellectual property portfolio.
• Clinical Validation: The company's focus on evidence-based, clinically validated software differentiates it from general wellness apps and builds trust within the medical community.
• First-Mover Advantage: As a pioneer in prescription digital therapeutics, Pear has gained early experience in navigating regulatory, commercial, and reimbursement challenges unique to this emerging field.

What Does PEAR Do?

Pear Therapeutics, Inc., founded in 2013 and headquartered in Boston, Massachusetts, operates as a commercial-phase medical company dedicated to the invention and distribution of digital therapeutics. The company's core mission revolves around developing software-based treatments designed to improve patient outcomes across various disease states. Its current commercialized portfolio includes reSET, a prescription digital therapeutic specifically engineered to address substance use disorders involving alcohol, cannabis, cocaine, and stimulants. Another key offering is reSET-O, which is prescribed in conjunction with buprenorphine to treat opioid use disorder, providing a comprehensive approach to a critical public health challenge. Furthermore, Pear Therapeutics offers Somryst, a digital solution designed to deliver cognitive behavioral therapy for chronic insomnia, a prevalent sleep disorder. Beyond these marketed therapies, Pear Therapeutics maintains an extensive and active development pipeline comprising 14 prospective products. These investigational treatments are diversified across multiple therapeutic areas, including psychiatry, neurology, and a range of non-central nervous system conditions such as gastrointestinal, oncological, and cardiovascular disorders. This broad pipeline underscores the company's commitment to expanding the application of digital therapeutics into new clinical domains, positioning it as a key innovator in the evolving landscape of digital health.

What Products and Services Does PEAR Offer?

• Develops and distributes prescription digital therapeutics (PDTs).
• Offers reSET for substance use disorders (alcohol, cannabis, cocaine, stimulants).
• Provides reSET-O for opioid use disorder, used alongside buprenorphine.
• Markets Somryst, a digital solution for chronic insomnia.
• Maintains a pipeline of 14 investigational products across psychiatry, neurology, and non-central nervous system conditions.
• Focuses on software-based treatments designed to improve patient outcomes.
• Headquartered in Boston, Massachusetts, and founded in 2013.

How Does PEAR Make Money?

• Generates revenue through the sale and distribution of its FDA-approved prescription digital therapeutics.
• Relies on healthcare providers prescribing its software-based treatments to patients.
• Potential for licensing agreements or partnerships for broader market access and development.
• Focuses on conditions with significant unmet needs, aiming for clinical validation and integration into standard medical practice.

What Industry Does PEAR Operate In?

Pear Therapeutics operates within the Medical - Healthcare Information Services industry, specifically pioneering the emerging field of prescription digital therapeutics (PDTs). This sector is characterized by the convergence of healthcare and technology, aiming to deliver evidence-based therapeutic interventions through software. The broader digital health market is experiencing significant growth, driven by increasing demand for accessible, scalable, and personalized healthcare solutions, particularly in mental health and chronic disease management. Pear Therapeutics distinguishes itself by developing FDA-authorized PDTs, which require rigorous clinical validation, setting a high barrier to entry. The competitive landscape includes other digital health companies, traditional pharmaceutical firms exploring digital adjuncts, and tech companies entering healthcare. Pear's position is defined by its focus on clinically validated, prescription-only software, aiming to integrate into established medical pathways rather than direct-to-consumer models, thereby navigating regulatory complexities and building trust within the medical community.

Who Are PEAR's Key Customers?

• Patients diagnosed with substance use disorders, opioid use disorder, and chronic insomnia who receive prescriptions for Pear's digital therapeutics.
• Healthcare providers (physicians, psychiatrists, addiction specialists) who prescribe Pear's products.
• Healthcare systems, hospitals, and clinics that integrate digital therapeutics into their treatment pathways.
• Health insurance payers who cover the cost of prescription digital therapeutics.

Company Profile

Pear Therapeutics, Inc. operates in the Medical - Healthcare Information Services industry within the Healthcare sector. It is headquartered in Boston, US. The company is led by CEO Christopher D. T. Guiffre MBA. PEAR has traded publicly since 2021.

F-Score 4/9Financial Health

Pear Therapeutics, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -6.61 places it in the distress zone, a signal of elevated financial risk.

ROE -39%Key Financial Metrics

Return on equity for Pear Therapeutics, Inc. stands at -39.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -25.0%, showing how much profit it generates from its asset base. A current ratio of 1.48 indicates the company holds enough short-term assets to cover its near-term obligations.

PEAR Valuation & Market Position

With a $4.09M market cap, Pear Therapeutics, Inc. sits in the micro-cap segment of the market. Relative to its peer group, PEAR's quantitative score of 64/100 is roughly in line with the peer average of 67/100.

Net buyingInsider Activity

The most recent 12 insider filings for Pear Therapeutics, Inc. break down as 2 sales and 10 purchases. On net that is roughly 6.8M shares acquired (about $445K) — insiders putting money in tends to read as conviction.

PEAR Financials

PEAR Latest News

PEAR Analyst Consensus

PEAR MoonshotScore

Common Questions About PEAR (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources